AYTU BIOPHARMA, INC Proceeds from (Payments for) Other Financing Activities
AYTU BIOPHARMA, INC (AYTU) reported Proceeds from (Payments for) Other Financing Activities of $0 for the 6-month period ending 2023-12-31, per its 10-Q filed 2024-02-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromPaymentsForOtherFinancingActivities · last filed 2024-02-14
- AYTU BIOPHARMA, INC proceeds from (payments for) other financing activities for the quarter ending 2022-12-31 was -$51.00K.
- AYTU BIOPHARMA, INC proceeds from (payments for) other financing activities for the quarter ending 2022-09-30 was -$13.00K.
- AYTU BIOPHARMA, INC proceeds from (payments for) other financing activities for the quarter ending 2022-06-30 was $0.00.
- AYTU BIOPHARMA, INC proceeds from (payments for) other financing activities for the quarter ending 2022-03-31 was -$1.00K.
- AYTU BIOPHARMA, INC proceeds from (payments for) other financing activities for fiscal 2022 was -$7.00K.
- AYTU BIOPHARMA, INC proceeds from (payments for) other financing activities for fiscal 2021 was -$5.00K.
- AYTU BIOPHARMA, INC proceeds from (payments for) other financing activities for fiscal 2020 was $0.00.
| Period end | Proceeds from (Payments for) Other Financing Activities 3 month | Proceeds from (Payments for) Other Financing Activities 6 month | Proceeds from (Payments for) Other Financing Activities 9 month | Proceeds from (Payments for) Other Financing Activities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-Q · filed 2024-02-14 | |||
| 2022-12-31 | -$51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | -$64.00K 10-Q · filed 2024-02-14 | -$64.00K derived: sum of 3 quarters · filed 2024-02-14 | -$65.00K derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-09-30 | -$13.00K 10-Q · filed 2023-11-14 | -$13.00K derived: sum of 2 quarters · filed 2023-11-14 | -$14.00K derived: sum of 3 quarters · filed 2023-11-14 | -$14.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | -$1.00K derived: sum of 2 quarters · filed 2023-10-12 | -$1.00K derived: sum of 3 quarters · filed 2023-10-12 | -$7.00K 10-K · filed 2023-10-12 |
| 2022-03-31 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | -$1.00K derived: sum of 2 quarters · filed 2023-05-11 | -$7.00K 10-Q · filed 2023-05-11 | |
| 2021-12-31 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-02-21 | -$6.00K 10-Q · filed 2023-02-21 | ||
| 2021-09-30 | -$6.00K 10-Q/A · filed 2023-02-21 | |||
| 2021-06-30 | -$5.00K 10-K · filed 2022-09-27 | |||
| 2020-06-30 | $0.00 10-K · filed 2021-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |